What the trial was testing
The JADE COMPARE enrolled 838 patients with atopic dermatitis. The study was sponsored by Pfizer and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Faster itch relief than dupilumab in the first two weeks at the higher dose.
New England Journal of Medicine · 2021 · NCT03720470
These findings — that itch relief in the first two weeks at the higher abrocitinib dose — were published in the New England Journal of Medicine and represent the headline result of the study.
Researchers tracked outcomes across 838 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with atopic dermatitis, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Abrocitinib (Cibinqo) is FDA-approved for moderate-to-severe atopic dermatitis in adults and available now. It is a once-daily pill — no injections. Side effects can include nausea, acne, and increased infection risk; regular blood tests are required. Ask a dermatologist whether it fits your case.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open atopic dermatitis trials
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
National Register of Moderate and Severe Adult Atopic Dermatitis
Collect clinical history and treatment data of AD in adulthood;